14.65
14.65 (0.00%)
| Open | 14.49 |
| Volume | 2,744 |
| Avg. Volume (3M) | 1,129,665 |
| Market Cap | 928,205,696 |
| Price / Earnings (TTM) | 10.24 |
| Price / Earnings (Forward) | 10.10 |
| Price / Sales | 2.59 |
| Price / Book | 1.36 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | 44.79% |
| Operating Margin (TTM) | 20.06% |
| Diluted EPS (TTM) | 2.23 |
| Quarterly Revenue Growth (YOY) | -3.00% |
| Quarterly Earnings Growth (YOY) | -23.20% |
| Total Debt/Equity (MRQ) | 0.90% |
| Current Ratio (MRQ) | 8.73 |
| Operating Cash Flow (TTM) | 122.59 M |
| Levered Free Cash Flow (TTM) | 73.58 M |
| Return on Assets (TTM) | 8.62% |
| Return on Equity (TTM) | 24.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | InMode Ltd. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.83 |
|
InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF, and Morpheus8, among others. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia, Israel, and other regions. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Value |
| % Held by Insiders | 15.35% |
| % Held by Institutions | 72.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| North Growth Management Ltd. | 31 Dec 2025 | 662,000 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | InMode to Participate in the 13th Annual BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference |
| 02 Feb 2026 | Announcement | InMode Responds to Transaction Rumors |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |